Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Israel
· Delayed Price · Currency is ILS · Price in ILA 1,180.00
-3.00 (-0.25%)
Apr 28, 2026, 5:24 PM IDT
TLV:REKA Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 300.99 | 321.71 | 321.66 | 292.39 | 263.95 | Upgrade
|
| Revenue Growth (YoY) | -6.44% | 0.01% | 10.01% | 10.78% | -0.57% | Upgrade
|
| Cost of Revenue | 231.42 | 249.76 | 241.46 | 213.69 | 198.79 | Upgrade
|
| Gross Profit | 69.57 | 71.95 | 80.2 | 78.71 | 65.16 | Upgrade
|
| Selling, General & Admin | 71.54 | 73.96 | 71.17 | 60.45 | 49.62 | Upgrade
|
| Research & Development | 4.3 | 3.83 | 3.65 | 3.23 | 2.08 | Upgrade
|
| Other Operating Expenses | 0.98 | 1.51 | 2.48 | 1.77 | 0.55 | Upgrade
|
| Operating Expenses | 76.81 | 79.29 | 77.3 | 65.46 | 52.25 | Upgrade
|
| Operating Income | -7.25 | -7.34 | 2.91 | 13.25 | 12.91 | Upgrade
|
| Interest Expense | -6.41 | -6.71 | -8.29 | -5.65 | -5.63 | Upgrade
|
| Interest & Investment Income | 0.37 | 0.36 | 0.71 | 0.04 | 0.07 | Upgrade
|
| Earnings From Equity Investments | -0.1 | 0.01 | -0.22 | - | -0.13 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.25 | 0.04 | -0.32 | 0.14 | -0.79 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.77 | -0.77 | -1.29 | -0.83 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | -14.41 | -14.4 | -6.5 | 6.96 | 6.48 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | -0.02 | 0.02 | -0.02 | 1.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.16 | 23.71 | 0.05 | 0 | 0.05 | Upgrade
|
| Other Unusual Items | 3.06 | -1.36 | -0.62 | -6.59 | - | Upgrade
|
| Pretax Income | -11.2 | 7.93 | -7.05 | 0.36 | 7.71 | Upgrade
|
| Income Tax Expense | 6.88 | 1.72 | -0.14 | 2.4 | 1.1 | Upgrade
|
| Earnings From Continuing Operations | -18.07 | 6.21 | -6.91 | -2.04 | 6.61 | Upgrade
|
| Net Income to Company | -18.07 | 6.21 | -6.91 | -2.04 | 6.61 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 0 | 0.01 | Upgrade
|
| Net Income | -18.07 | 6.21 | -6.91 | -2.04 | 6.62 | Upgrade
|
| Net Income to Common | -18.07 | 6.21 | -6.91 | -2.04 | 6.62 | Upgrade
|
| Net Income Growth | - | - | - | - | -38.65% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| EPS (Basic) | -1.58 | 0.54 | -0.61 | -0.18 | 0.58 | Upgrade
|
| EPS (Diluted) | -1.58 | 0.54 | -0.61 | -0.18 | 0.58 | Upgrade
|
| EPS Growth | - | - | - | - | -38.65% | Upgrade
|
| Free Cash Flow | 5.92 | 17.85 | 16.86 | 32.07 | 7.68 | Upgrade
|
| Free Cash Flow Per Share | 0.52 | 1.56 | 1.48 | 2.81 | 0.67 | Upgrade
|
| Dividend Per Share | - | - | - | - | 0.868 | Upgrade
|
| Gross Margin | 23.11% | 22.36% | 24.93% | 26.92% | 24.69% | Upgrade
|
| Operating Margin | -2.41% | -2.28% | 0.90% | 4.53% | 4.89% | Upgrade
|
| Profit Margin | -6.00% | 1.93% | -2.15% | -0.70% | 2.51% | Upgrade
|
| Free Cash Flow Margin | 1.97% | 5.55% | 5.24% | 10.97% | 2.91% | Upgrade
|
| EBITDA | 15.34 | 25.18 | 32.82 | 40.73 | 35.77 | Upgrade
|
| EBITDA Margin | 5.10% | 7.83% | 10.20% | 13.93% | 13.55% | Upgrade
|
| D&A For EBITDA | 22.59 | 32.52 | 29.92 | 27.48 | 22.86 | Upgrade
|
| EBIT | -7.25 | -7.34 | 2.91 | 13.25 | 12.91 | Upgrade
|
| EBIT Margin | -2.41% | -2.28% | 0.90% | 4.53% | 4.89% | Upgrade
|
| Effective Tax Rate | - | 21.72% | - | 672.27% | 14.21% | Upgrade
|
| Advertising Expenses | 3.46 | 2.51 | 3.16 | 1.3 | 1.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.